Multiple clinical data readouts expected in 2026 present opportunity for substantial value creation
KOASTAL-2 and -3 on track for consolidated topline readout in the second quarter of 2026
Plans to conduct NMRA-215 clinical program in 2026 following class-leading preclinical data from diet induced obesity model
Advancing NMRA-511 following Phase 1b results demonstrating clinically meaningful effect on CMAI total score
Cash, cash equivalents and marketable securities expected to support operations into the third quarter of 2027
WATERTOWN, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) — Neumora Therapeutics, Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced key pipeline updates and anticipated 2026 milestones that support the Company’s mission to redefine neuroscience drug development with the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases.
“2025 was a productive and strategically important year for Neumora, as we advanced our pipeline of novel mechanism therapies, prioritized obesity as the lead indication for our highly brain-penetrant NLRP3 inhibitor, NMRA-215, expanded our M4 PAM franchise with two new programs in clinical development, progressed the Phase 3 program for navacaprant, and produced compelling data for NMRA-511 – all while continuing to strengthen our financial foundation,” said Paul L. Berns, co-founder, chairman and chief executive officer of Neumora. “This progress set up important expected milestones across our programs. We are entering a catalyst-rich period that I believe will meaningfully shape the future of Neumora, as well as the future of treatment for several underserved disease areas. Supported by a strong team, we are well-positioned to execute on our goal to advance a next generation of therapies for people living with brain diseases.”
2026 PIPELINE STRATEGY
Navacaprant: Planned joint readout of KOASTAL-2 and -3 in second quarter of 2026
Neumora today …